secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001104659-25-100646
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025
--------------------------------------------------------------------------------

- In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).
- In DKK1-high (upper quartile, n=44): mPFS 9.36 vs 5.88 mo (HR 0.46, p=0.017); mOS not reached vs 9.66 mo (HR 0.17, p<0.001).
- Full ITT (n=188): mPFS 9.2 vs 8.3 mo (HR 0.84, p=0.171); ORR 35.1% vs 26.6%.
- Sirexatamab well tolerated; TEAE profile similar between arms.
- Leap plans to engage regulators on registrational path for sirexatamab in CRC; supported by recent financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925100646/0001104659-25-100646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925100646/tm2529085d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer